Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cronos Group Inc. stock logo
CRON
Cronos Group
$2.08
$1.97
$1.60
$2.54
$802.22M1.031.35 million shs1.45 million shs
Evolus, Inc. stock logo
EOLS
Evolus
$9.66
+4.3%
$9.85
$8.67
$17.82
$597.04M0.97757,745 shs898,693 shs
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$3.71
+0.7%
$4.12
$2.55
$6.42
$184.01M1.0810,456 shs694 shs
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
$2.38
+16.1%
$2.14
$1.54
$3.97
$697.54M1.333.02 million shs13.92 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cronos Group Inc. stock logo
CRON
Cronos Group
0.00%+4.00%+6.12%+23.81%-7.14%
Evolus, Inc. stock logo
EOLS
Evolus
+4.32%+4.89%+0.10%+2.66%-13.52%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
+0.71%-2.60%-12.80%+13.68%-12.18%
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
+16.10%+15.82%-5.18%+35.61%-25.86%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cronos Group Inc. stock logo
CRON
Cronos Group
2.2554 of 5 stars
0.05.00.00.01.90.02.5
Evolus, Inc. stock logo
EOLS
Evolus
3.692 of 5 stars
3.50.00.03.51.13.30.6
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
1.5002 of 5 stars
3.54.00.00.00.00.00.0
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
3.4645 of 5 stars
4.60.00.00.03.34.20.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cronos Group Inc. stock logo
CRON
Cronos Group
0.00
N/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
3.00
Buy$23.75145.86% Upside
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
3.00
Buy$13.00250.78% Upside
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
3.20
Buy$7.17201.12% Upside

Current Analyst Ratings Breakdown

Latest GNFT, NUVB, CRON, and EOLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$6.00
6/17/2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$10.00 ➝ $6.00
6/11/2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$5.00
6/2/2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$6.00
5/15/2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.00
5/8/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
4/23/2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
4/23/2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMkt Outperform$6.00
4/23/2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Outperform$6.00
4/17/2025
Evolus, Inc. stock logo
EOLS
Evolus
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
4/10/2025
Evolus, Inc. stock logo
EOLS
Evolus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cronos Group Inc. stock logo
CRON
Cronos Group
$124.59M6.44$0.00 per share4,470.04$2.90 per share0.72
Evolus, Inc. stock logo
EOLS
Evolus
$266.27M2.34N/AN/A$0.09 per share107.33
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$67.00M2.77$0.07 per share52.61$1.50 per share2.47
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
$7.87M102.90N/AN/A$1.37 per share1.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cronos Group Inc. stock logo
CRON
Cronos Group
$41.08M$0.1316.0069.33N/A39.69%-0.07%-0.07%8/6/2025 (Estimated)
Evolus, Inc. stock logo
EOLS
Evolus
-$50.42M-$0.89N/AN/AN/A-20.40%-759.04%-20.14%7/30/2025 (Estimated)
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$1.63MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
-$567.94M-$2.35N/AN/AN/A-5,534.21%-44.14%-32.97%8/4/2025 (Estimated)

Latest GNFT, NUVB, CRON, and EOLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
-$0.17N/AN/AN/A$0.42 millionN/A
7/30/2025Q2 2025
Evolus, Inc. stock logo
EOLS
Evolus
-$0.09N/AN/AN/A$82.18 millionN/A
5/8/2025Q1 2025
Cronos Group Inc. stock logo
CRON
Cronos Group
$0.01$0.02+$0.01$0.02$45.44 million$33.62 million
5/7/2025Q1 2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
-$0.16-$0.16N/A-$0.16$0.42 million$3.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cronos Group Inc. stock logo
CRON
Cronos Group
N/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
N/AN/AN/AN/AN/A
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cronos Group Inc. stock logo
CRON
Cronos Group
N/A
27.80
26.75
Evolus, Inc. stock logo
EOLS
Evolus
22.00
2.34
2.16
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
0.08
1.23
1.23
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
N/A
9.01
9.01

Institutional Ownership

CompanyInstitutional Ownership
Cronos Group Inc. stock logo
CRON
Cronos Group
8.71%
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
2.24%
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
61.67%

Insider Ownership

CompanyInsider Ownership
Cronos Group Inc. stock logo
CRON
Cronos Group
7.30%
Evolus, Inc. stock logo
EOLS
Evolus
5.90%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
4.20%
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
29.93%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cronos Group Inc. stock logo
CRON
Cronos Group
450385.68 million357.53 millionOptionable
Evolus, Inc. stock logo
EOLS
Evolus
17064.48 million60.67 millionOptionable
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
12050.00 million47.90 millionNot Optionable
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
60340.26 million238.42 millionOptionable

Recent News About These Companies

Analysts Set Nuvation Bio Inc. (NYSE:NUVB) PT at $7.17
Nuvation Bio (NYSE:NUVB) Shares Gap Up - What's Next?
Nuvation Bio (NYSE:NUVB) Shares Gap Up - Here's Why
Founder of Nuvation Bio David Hung Buys More Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cronos Group stock logo

Cronos Group NASDAQ:CRON

$2.08 0.00 (0.00%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$2.09 +0.01 (+0.48%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Evolus stock logo

Evolus NASDAQ:EOLS

$9.66 +0.40 (+4.32%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$9.68 +0.02 (+0.16%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

GENFIT stock logo

GENFIT NASDAQ:GNFT

$3.71 +0.03 (+0.71%)
As of 07/9/2025 12:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Nuvation Bio stock logo

Nuvation Bio NYSE:NUVB

$2.38 +0.33 (+16.10%)
Closing price 07/9/2025 03:57 PM Eastern
Extended Trading
$2.39 +0.01 (+0.59%)
As of 05:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.